Navigation Links
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Date:11/29/2007

ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)announced today that the Circulatory System Devices Advisory Panel to the U.S. Food and Drug Administration (FDA) recommended approval for the XIENCE(TM) V Everolimus Eluting Coronary Stent System. XIENCE V is a next-generation drug eluting stent intended for use in the treatment of coronary artery disease.

The FDA advisory committee voted to recommend the XIENCE V stent system for approval with conditions related to post-marketing study requirements and language related to dual antiplatelet therapy. The FDA is not required to, but usually follows the recommendations of its advisory committees.

"The clinical and angiographic benefits of the XIENCE V stent compared to the most widely used drug eluting stent available in the U.S. have been consistent and significant across the SPIRIT trials," said Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation, New York and principal investigator of the SPIRIT III clinical trial. "The robust body of safety and efficacy data support approval of XIENCE V as an important new technology that will enhance the lives of millions of patients with heart disease."

Abbott filed its Premarket Approval (PMA) submission for XIENCE V with the FDA on June 1, 2007. The PMA for XIENCE V is the first to include data demonstrating superiority of one drug eluting stent over another in the primary endpoint of in-segment late loss in a randomized controlled head-to-head trial with a market leading product.

"The outcome of today's advisory committee meeting is very encouraging," said John M. Capek, Ph.D., executive vice president, Medical Products, Abbott. "We look forward to bringing this important new treatment for coronary artery disease to physicians and patients in the U.S."

XIENCE V was launched in Europe and other international markets in 2006. XIENCE V is currently an investigational
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 National Geographic questioned in an article ... of remembrance is getting lost in the swirl of summer ... and prompted some research and analysis on the subject based ... A statistical evaluation of around 180 ecards shared by Americans, ... the emotions of fun and celebration. In the modern ...
(Date:5/24/2013)... Lake City, UT (PRWEB) May 24, 2013 ... MonaVie Latin America, as a new member of the Ethics ... “I am proud to have been elected to this council ... ethical basis of the direct selling industry,” says Patrocinio. , ... a positive contributor to Brazil’s economy. The direct selling industry ...
(Date:5/24/2013)... This report “EpiCast Report: Meningococcal Disease ... the risk factors and global trends for meningococcal disease ... Spain, UK, Australia, and Brazil). It includes a 10-year ... by age (<1, 1–4, 5–14, 15–24, 25–44, 45–64, and ... in these markets. The other serogroups, namely serogroups A ...
(Date:5/24/2013)... According to the new market research report “Micro ... 2016)” published by MarketsandMarkets, global micro irrigation system market ... of year 2010 and is expected to reach $3,414.7 ... from 2011 to 2016. , Browse:, , ... Figures , 370 pages and in-depth Table ...
(Date:5/24/2013)... Just about any bodyweight training program includes a variety of ... Dallas, GA that uses a variety of bodyweight conditioning circuits ... used enough. , “The medicine ball pushup is ... By keeping your hands on a medicine ball, the core ... much harder than a standard pushup. This unique bodyweight chest ...
Breaking Medicine News(10 mins):Health News:Is Memorial Day More Than A Three-Day Weekend 2Health News:MonaVie Brazil Executive Elected to Ethics Board of ABEVD 2Health News:Meningococcal Disease Market Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com 2Health News:Meningococcal Disease Market Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com 3Health News:Meningococcal Disease Market Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com 4Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2
... Million Americans Have Parkinson,s Disease, Roughly ... ... 21 Accolade, a Texas-based home,healthcare and hospice provider, observes ... Parkinson,s disease.,Accolade,s innovative short-term program enables people living with the,disease ...
... proved more beneficial than individual grief counseling, study finds ... experience the unexpected death of a parent after a ... finding that has major implications for helping children deal ... "Often children who have lost a parent are given ...
... than 6 millimeters in diameter appear more likely to ... in the April issue of Archives of Dermatology, one ... diameter guidelines currently used by dermatologists to screen for ... method to screen for melanoma, according to background information ...
... Decisions on Bottom Line Return at 3rd Annual ... Pharmaceutical Market Research Summit, NEW ... the pharmaceutical analytics company Eularis, will be,delivering a presentation on ... Research and Decisions on Bottom Line Return., ...
... of West Nile Virus and Other Diseases, SACRAMENTO, ... in hand. Coinciding with the launch of mosquito season, ... to April 25,2008 West Nile Virus and Mosquito and ... a mosquito-borne disease that can result in,debilitating cases of ...
... suggests , , MONDAY, April 21 (HealthDay News) -- The ... disease than women appear during the adolescent years, according a ... , "This is not what we would have predicted," said ... the University of Minnesota Children,s Hospital, and lead author of ...
Cached Medicine News:Health News:April is National Parkinson's Disease Awareness Month 2Health News:April is National Parkinson's Disease Awareness Month 3Health News:Treating PTSD Helps Kids Deal With Loss 2Health News:Larger skin lesions appear more likely to be melanomas 2Health News:Eularis to Address Making the Right Research Decision for ROI 2Health News:State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week 2Health News:Heart Disease Risks Hit Boys in Teens 2
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" ... specialty products, announced today that Dr. Robert Grieve ... Jason Napolitano , executive vice president and ... MicroCap Conference, which is being held May 30, 2013 in ... Hyatt Hotel. The Company,s presentation is scheduled ...
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
Super High Density, multi-frequency, phased array burr hole transducer. Excellent for taking biopsy samples and shunt placements....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
Medicine Products: